原因之一可能是一些大型制药公司认为和解是买通仿制药品公司使之延迟推出降价药品时间的手段。
One reason could be that some drugs giants regard settlements as a way to bribe a generics firm to delay its introduction of a cut-price product.
瑞士诺华制药公司认为，药片不应只向血流中输送药物，还应该能够监测其效果，并把数据传送给医生。
Swiss pharma house Novartis thinks pills needn't merely deliver medicine to the bloodstream, but could also monitor its effects and transmit data to physicians.
制药公司认为，高昂的开发与生产成本，以及对利润的追求，即便这种药品的销售量很小，也势必使它的药价水涨船高攀升至高点。
High prices for such drugs are justified, companies say, by high development and production costs and the need for profits, even if sales are small.
应用推荐